Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function.

Area of Science:

• Biochemistry
• Oncology
• Cell Biology

Background:

• Cancer-induced bone disease leads to bone destruction, fractures, and pain.
• Osteoclast differentiation and function are critical in bone remodeling and disease progression.
• The proteasome-ubiquitin system and NF-kappaB signaling are key regulators of osteoclastogenesis.

Purpose of the Study:

• To investigate the effects of proteasome inhibitors MG-132 and MG-262 on osteoclast differentiation and function.
• To determine if inhibiting the proteasome-ubiquitin system can mitigate receptor activator of NF-kappaB ligand (RANKL)-mediated osteoclast activity.
• To explore the therapeutic potential of proteasome inhibitors in treating cancer-induced bone disease.

Main Methods:

• Osteoclast precursors were differentiated using RANKL and M-CSF.
• Proteasome inhibitors MG-132 and MG-262 were applied at sub-apoptotic concentrations.
• Osteoclast differentiation was assessed by TRAP-positive multinucleated cell counts.
• Osteoclast function was evaluated by dentine resorption assays and TRAP activity.
• NF-kappaB binding capacity was analyzed in treated and untreated osteoclasts.

Main Results:

• MG-132 and MG-262 significantly inhibited osteoclast differentiation in a dose-dependent manner.
• Both inhibitors markedly reduced osteoclast resorption capacity and TRAP activity.
• The observed decrease in osteoclast function correlated with reduced NF-kappaB binding.
• Low concentrations of proteasome inhibitors were sufficient to impact osteoclastogenesis.

Conclusions:

• Proteasome inhibitors MG-132 and MG-262 effectively suppress osteoclast differentiation and function.
• These inhibitors demonstrate potential as therapeutic agents for managing cancer-induced osteolytic bone lesions.
• Targeting the proteasome-ubiquitin system offers a promising strategy for treating bone destruction in cancer patients.